🏛️ Verified NIH Record • Updated 2026-05-04

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (NCT01042379)

I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: QuantumLeap Healthcare Collaborative

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.

Who can join: Review the eligibility criteria below.

Location: University of Alabama at Birmingham — Birmingham, Alabama

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (42 Sites)

Showing the first 25 of 42 sites.

  • University of Alabama at Birmingham — Birmingham, Alabama
  • Mayo Clinic - Scottsdale — Scottsdale, Arizona
  • University of Arizona — Tucson, Arizona
  • University of California - Davis, Comprehensive Cancer Center — Davis, California
  • City of Hope — Duarte, California
  • University of California San Diego — La Jolla, California
  • University of Southern California — Los Angeles, California
  • HOAG Memorial Hospital Presbyterian — Newport Beach, California
  • University of California San Francisco (UCSF) — San Francisco, California
  • University of Colorado Cancer Center — Aurora, Colorado
  • Yale Cancer Center — New Haven, Connecticut
  • Georgetown University Medical Center — Washington D.C., District of Columbia
  • H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
  • Moffitt Cancer Center — Tampa, Florida
  • Winship Cancer Institute of Emory University — Atlanta, Georgia
  • University of Chicago — Chicago, Illinois
  • Loyola University — Maywood, Illinois
  • University of Kansas — Westwood, Kansas
  • Herbert-Herman Cancer Center, Sparrow Hospital — Lansing, Michigan
  • University of Minnesota — Minneapolis, Minnesota
  • Mayo Clinic — Rochester, Minnesota
  • Metro Minnesota Community Oncology Research Consortium, Hennepin County Medical Center — Saint Louis Park, Minnesota
  • Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
  • Roswell Park Cancer Institute — Buffalo, New York
  • Laura and Isaac Perlmutter Cancer Center / NYU Langone Health — New York, New York

📞 Contact the Study Coordinator

Phone: (855) 866-0505

Email: w.chang@quantumleaphealth.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Breast Neoplasms

Explore by condition: All Breast Neoplasms clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗